PolTREG announces it has received a Notice of Allowance from the US Patent Office covering the manufacturing of T-regulatory cells (T-reg) to treat Type-1 Diabetes (T1D), and ways the therapy is administered. The decision paves “the way for rapid, unimpeded commercialization of PolTREG’s cell therapies,” CEO Prof. Piotr Trzonkowski was quoted as saying in today’s
PolTREG has the most advanced pipeline for Treg cell therapies in autoimmune disease, with its flagship drug candidate, PTG-007, in clinical studies for two indications in T1D and two in Multiple Sclerosis (MS).
